BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01711632 |
Recruitment Status :
Active, not recruiting
First Posted : October 22, 2012
Last Update Posted : August 1, 2023
|
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Cancer Institute (NCI)
Northwestern University
Ohio State University
Dana-Farber Cancer Institute
Scripps Clinic
Northwell Health
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | October 2025 |
Estimated Study Completion Date : | October 2025 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):